Celgene Hit With Expansive Antitrust Suit Over Thalomid
A health fund hit Celgene Corp. with a proposed class action Thursday in New Jersey federal court over the company's alleged anti-competitive behavior meant to keep its monopoly on the drugs Thalomid...To view the full article, register now.
Already a subscriber? Click here to view full article